Innovating Works

MossTOR

Financiado
Investigating the TORC1 signaling pathway in the moss Physcomitrella and its app...
Investigating the TORC1 signaling pathway in the moss Physcomitrella and its application for enhanced production of valuable pharmaceutical compounds The Target of Rapamycin Complex 1 (TORC1) signaling pathway, involved in the coordination of cell growth and metabolism, is highly conserved among eukaryotes, including seed plants and algae. Studies have shown that its activity c... The Target of Rapamycin Complex 1 (TORC1) signaling pathway, involved in the coordination of cell growth and metabolism, is highly conserved among eukaryotes, including seed plants and algae. Studies have shown that its activity could be tuned to enhance plant growth, yield and resistance to stress, or accumulation of triacylglycerol in algae, thus indicating that its power could be harnessed to improve diverse plant biotechnological applications. In this project, I aim to characterize the TORC1 pathway for the first time in the moss Physcomitrella (Physcomitrium patens), a model organism of non-seed plants, using protonema cells as a study system. This is linked to another important goal, to test whether the activity of TORC1 can be modulated in order to improve moss-based biotechnological applications. Besides the identification of a functional TORC1 in Physcomitrella, I will develop transgenic lines with hyperactive TORC1 signaling, phenotypically and metabolically analyzing them, and in collaboration with Mosspiration Biotech, test if these lines could produce more human recombinant complement proteins or the drug artemisinin, used to treat patients with complement disorders or malaria, respectively. Enhancing this yield will result in a stable, sustainable and eco-friendly production platform. It would also lead to a reduced price, for instance of artemisinin-based treatments, thus allowing poor communities most affected by malaria to contain the disease. Should this project be successful, it will open the door to improve the yield of diverse well-established products from Physcomitrella, valuable metabolites, active pharmaceutical ingredients and biopharmaceutical proteins. ver más
31/01/2025
237K€
Duración del proyecto: 31 meses Fecha Inicio: 2022-06-02
Fecha Fin: 2025-01-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-02
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 237K€
Líder del proyecto
ALBERTLUDWIGSUNIVERSITAET FREIBURG No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5